Reviewing Anika Therapeutics Inc. (ANIK)’s and Ophthotech Corporation (:)’s results

Anika Therapeutics Inc. (NASDAQ:ANIK) and Ophthotech Corporation (:) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics Inc. 41 7.18 N/A 2.05 26.83
Ophthotech Corporation N/A 0.00 N/A 1.70 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Anika Therapeutics Inc. and Ophthotech Corporation.

Profitability

Table 2 has Anika Therapeutics Inc. and Ophthotech Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics Inc. 0.00% 7.2% 6.7%
Ophthotech Corporation 0.00% 0% 0%

Institutional & Insider Ownership

Roughly 96.6% of Anika Therapeutics Inc. shares are held by institutional investors while 65.14% of Ophthotech Corporation are owned by institutional investors. Insiders held 0.9% of Anika Therapeutics Inc. shares. On the other hand, insiders held about 0.61% of Ophthotech Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anika Therapeutics Inc. 34.96% 36.13% 68.01% 45.28% 39.72% 63.91%
Ophthotech Corporation 0% 0% 0% 0% 0% 0%

Summary

On 8 of the 8 factors Anika Therapeutics Inc. beats Ophthotech Corporation.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.